Executive Summary
This deobligations alert reveals $5.98B in sustained federal contract obligations, dominated by 17 bullish signals including a $1.35B HHS vaccine facility for Seqirus and $629M DHS border wall commitments to Barnard/Spencer, signaling robust infrastructure and security spending into 2026+. IT/services firms like CACI ($921M GSA), Oracle ($300M VA), and Peraton ($219M Treasury) show strong multi-year revenue visibility through 2026-2034 despite low outlays in many cases. Risks center on execution delays from future awards (e.g., 2026 border projects) and firm-fixed-price exposures, but unexercised options offer $2B+ upside.
Tracking the trend? Catch up on the prior Contract Deobligations Alert digest from January 27, 2026.
Investment Signals(4)
- Border wall surge at DHS/CBP(HIGH)▲
Two $629M obligations to Barnard/Spencer for RGV-1 barriers awarded 2026-01-27 signal policy-driven infrastructure spend despite $0 outlays.
- Vaccine manufacturing commitment(HIGH)▲
$1.35B HHS obligation to Seqirus (options to $2.21B) for long-term facility build underscores biopharma resilience through 2029-2034.
- Fed IT/services pipeline expansion(HIGH)▲
CACI ($921M GSA), Oracle ($300M VA), Peraton ($219M Treasury) highlight $2B+ in IT contracts to 2026-2030 with 70%+ outlay progress in leaders.
- Low outlay execution gaps(MEDIUM)▲
13/19 contracts show $0 or minimal outlays vs. obligations (e.g., $369M Barnard, $300M Oracle), flagging potential funding delays.
Risk Flags(3)
- Execution[HIGH RISK]▼
Future award dates (2026-01-27 for $629M border wall) and $0 outlays across 8 contracts risk delays/non-starts amid fiscal scrutiny.
- Market[MEDIUM RISK]▼
Firm-fixed-price in 9 contracts (e.g., $265M Honeywell to 2034) exposes margins to cost overruns over extended periods.
- Execution[MEDIUM RISK]▼
Long tenors to 2034 (Seqirus, Honeywell, Southwest Research) vulnerable to budget shifts/geopolitics (e.g., USAID Ukraine).
Opportunities(3)
- ◆
$2B+ unexercised options (e.g., Seqirus $861M, Raytheon $322M to $400M, Southwest $103M) provide near-term upside if exercised.
- ◆
DHS border ($629M), DOE lab ($475M), NASA R&D ($199M GE + $68M SwRI) signal multi-year infra/R&D stability.
- ◆
High subawards (e.g., $392M CACI, $79M Accenture) in primes offer supply chain entry for smaller players.
Sector Themes(3)
- ◆
$629M DHS obligations for RGV-1 walls to private constructors amid $0 outlays signal renewed priority spending.
- ◆
70% of value in IT/health/R&D contracts to 2026-2034 (CACI, Oracle, Seqirus, NASA) with full competition wins.
- ◆
$1.35B vaccine + $475M DOE lab ops highlight sustained health/environmental mandates.
Watch List(3)
- 👁
{"entity"=>"Seqirus Inc", "reason"=>"$1.35B obligation (62% of total) with $861M options to 2034 dominates period.", "trigger"=>"option exercise or outlay >$500M"}
- 👁
{"entity"=>"Barnard/Spencer Construction", "reason"=>"$629M border wall at risk from 2026 award/$0 outlay.", "trigger"=>"performance start or cancellation"}
- 👁
{"entity"=>"CACI Intl subsidiaries", "reason"=>"$1.14B across GSA/DHS IT with subawards signaling ecosystem growth.", "trigger"=>"negative outlay resolution or new BPAs"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 19 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC